CILUPREVIR

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C40H50N6O8S
Molecular Weight	774.925
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC2=C(C=C1)C(O[C@@H]3C[C@@H]4N(C3)C(=O)[C@H](CCCCCC=C[C@@H]5C[C@]5(NC4=O)C(O)=O)NC(=O)OC6CCCC6)=CC(=N2)C7=CSC(NC(C)C)=N7

InChI

InChIKey=PJZPDFUUXKKDNB-KNINVFKUSA-N

InChI=1S/C40H50N6O8S/c1-23(2)41-38-43-32(22-55-38)31-19-34(28-16-15-26(52-3)17-30(28)42-31)53-27-18-33-35(47)45-40(37(49)50)20-24(40)11-7-5-4-6-8-14-29(36(48)46(33)21-27)44-39(51)54-25-12-9-10-13-25/h7,11,15-17,19,22-25,27,29,33H,4-6,8-10,12-14,18,20-21H2,1-3H3,(H,41,43)(H,44,51)(H,45,47)(H,49,50)/b11-7-/t24-,27-,29+,33+,40-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C40H50N6O8S
Molecular Weight	774.925
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	5 / 5
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17155849 | https://www.clinicaltrials.gov/ct2/show/NCT02226939

Ciluprevir (BILN-2061) is a selective inhibitor of the HCV NS3 serine protease, which was developed by Boehringer Ingelheim for the treatment of hepatitis C infection. The drug was discontinued in phase II due to adverse events such as cardiac toxicity (demonstrated in animals). In the cell-based replicon assay, ciluprevir inhibited HCV RNA replication at low nanomolar levels. It had inhibitory rate constant (Ki) values of 0.3 and 0.66 nM for the NS3 proteases of HCV genotypes 1a and -1b, respectively.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Hepatitis C virus NS3 protease/helicase 5 Target ID: CHEMBL4893 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17002221	Inhibitor 8504		3.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hepatitis C 42 Sources: https://www.clinicaltrials.gov/ct2/show/NCT02226939	Primary		Phase II 1147	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
1189.16 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15732092	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		CILUPREVIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
2799.99 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15732092	10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:		CILUPREVIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
5323.08 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15732092	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		CILUPREVIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN
13318.27 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15732092	10 mg 1 times / day multiple, oral dose: 10 mg route of administration: Oral experiment type: MULTIPLE co-administered:		CILUPREVIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN

Sourcing

Vendor/Aggregator	ID	URL
AK Scientific	3548AH	https://aksci.com/item_detail.php?cat=3548AH
AstaTech	43144	http://astatechinc.com/CPSResult.php?CRNO=43144
eMolecules	176929104	https://orderbb.emolecules.com/search/#?query=176929104
Molnova	M13936	https://www.molnova.com/en/serch-list.html?keywords=M13936
MuseChem	I006005	https://www.musechem.com/product/I006005.html

PubMed

Title	Date	PubMed
Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug.	2014	24419349
Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451.	2014	23939899
In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.	2013-11	24013001
Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.	2012-04-12	22471376
Inhibitory effects of polyphenols toward HCV from the mangrove plant Excoecaria agallocha L.	2012-01-15	22196120
Novel, potent, and orally bioavailable phosphinic acid inhibitors of the hepatitis C virus NS3 protease.	2011-06-15	21601450
Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors.	2011-05	20456634
A twenty-eight-day mechanistic time course study in the rhesus monkey with hepatitis C virus protease inhibitor BILN 2061.	2011-04	21441227
Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335).	2010-09-09	20715823
Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents.	2010-07-15	20541424
MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.	2010-01	19841155
Advances in the development of macrocyclic inhibitors of hepatitis C virus NS3-4A protease.	2010	20536420
New small molecule inhibitors of hepatitis C virus.	2009-12-15	19896376
Hepatitis C virus NS3 protease is activated by low concentrations of protease inhibitors.	2009-12-08	19839643
Substituted imidazopyridines as potent inhibitors of HCV replication.	2009-05	19303654
Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227).	2008-12	18824605
Synergy of a hepatitis C virus (HCV) NS4A antagonist in combination with HCV protease and polymerase inhibitors.	2008-05	18332167
Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse.	2007-10	17919490
Phenylglycine as a novel P2 scaffold in hepatitis C virus NS3 protease inhibitors.	2007-02-01	17113777
Potent inhibitors of the hepatitis C virus NS3 protease: use of a novel P2 cyclopentane-derived template.	2006-08-01	16675222
In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.	2005-11-04	16087668
Control of hepatitis C: a medicinal chemistry perspective.	2005-01-13	15633995
In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms.	2004-04-23	14766754
Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.	2004-03-25	15027850
An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.	2003-11-13	14578911

Sample Use Guides

In Vivo Use Guide

In a clinical trial, cipuprevir was given at a dose of 200 mg p.o. at two consecutive days, two times daily.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:18:22 GMT 2025` Edited by `admin` on `Mon Mar 31 18:18:22 GMT 2025`
Record UNII	75C8DU40T0
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CILUPREVIR

Official Name

English

BILN 2061 ZW

Preferred Name

English

(2R,6S,12Z,13aS,14aR,16aS)-6-[[(Cyclopentyloxy)carbonyl]amino]-2-[[7-methoxy-2-[2-[(1-methylethyl)amino]thiazol-4-yl]quinolin-4-yl]oxy]-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[E]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14

Systematic Name

English

CILUPREVIR [USAN]

Common Name

English

BILN-2061-ZW

Code

English

BILN-2061

Code

English

ciluprevir [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C281